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tion consisting of three dimensions, which explained
73.6% of the variance. Cronbach’s alpha was 0.92 for the
13 ﬁnal items. CONCLUSIONS: The subscales: ease of
use (a = 0.91), activity interference (a = 0.86), and social
acceptability (a = 0.82) relating to expectations satisﬁed
the criteria for scale reliability and validity. Subsequent
use in measuring satisfaction prior to and after product
experience is warranted.
HEMATOLOGIC/PITUITARY DISORDERS—
Economic Outcomes
PPT1
COST-EFFECTIVENESS OF RECOMBINANT
HUMAN ERYTHROPOIETIN FOR PREVENTING
TRANSFUSIONS IN CRITICALLY ILL PATIENTS
Sullivan PW, MacLaren R
University of Colorado School of Pharmacy, Denver,
CO, USA
OBJECTIVES: Anemia occurs in approximately 75–95%
of patients admitted to the ICU for at least 3 days and is
associated with lengthened intensive care unit (ICU) stay
and increased mortality. However, red blood cell (RBC)
transfusion is also associated with deleterious effects and
may increase mortality. The objective of this analysis was
to examine the cost-effectiveness of using recombinant
human erythropoietin (rHuEPO) to prevent or reduce the
use of RBC transfusions in a mixed (medical/surgical/
trauma) ICU. METHODS: The authors used decision
analysis to examine the immediate and lifetime costs and
effectiveness of using rHuEPO. The model included: fea-
sibility (the deferral rate for allogeneic RBC transfus-
ions), rHuEPO efﬁcacy (the reduction in allogeneic RBC
use), and adverse effects of rHuEPO and allogeneic 
RBC transfusions. Adverse effects of rHuEPO included
deep venous thrombosis (DVT) and thrombocytopenia.
Adverse effects of RBC transfusion included acute lung
injury (ALI), hemolytic reaction (HR), and febrile reac-
tions (FR) including hepatitis B (HB), hepatitis C (HC),
human immunodeﬁciency virus (HIV), and human T-cell
lymphotrophic virus (HTLV). Effectiveness was measured
using discounted quality-adjusted life years (QALYs).
Costs are expressed in 2002 U.S. dollars using 3% as the
discount rate. Univariate sensitivity analysis was con-
ducted to examine the impact of uncertainty in the para-
meter estimates on the results of the model. RESULTS:
For the base case analysis, the cost-effectiveness of using
rHuEPO to prevent anemia- related RBC transfusions
was $17,806,000/QALY. Results of the sensitivity analy-
ses revealed that the cost and total dose or units trans-
fused of rHuEPO and RBC transfusion had the greatest
impact on the expected cost of therapy. QALY decrements
associated with adverse effects had minimal impact on the
expected effectiveness of treatment. CONCLUSIONS: It
is unlikely that the use of rHuEPO to prevent or reduce
RBC transfusions in a mixed ICU population is cost-
effective.
PPT2
COST ANALYSIS OF PROPHYLACTIC
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OBJECTIVES: Hemophilia A is a rare hereditary bleed-
ing disorder with serious consequences. Replacement
therapy is normally administered, either prophylactically
or on demand. Economic aspects have been little
researched. Therefore, we conducted a cost analysis using
data from the Hemophilia Treatment Centre in London,
Canada, where all patients are treated prophylactically.
METHODS: We reviewed charts of all severe hemophilia
patients (n = 6) from time of diagnosis until the present,
identifying resources consumed, then costing from the
Ministry of Health perspective. Patients having com-
plications, such as inhibitors, HIV, or hepatitis, were
excluded. For each subject, we determined the costs of
Factor VIII, hospitalization, port-A-catheter insertions
and complications, treatments, homecare and physi-
cian/clinic visits, in Canadian 1997 dollars, discounted at
3%. RESULTS: Data were available from 1988 to 1999.
The total average cost (range) was $51,994 ($2171–
$75,516)/patient/year. Factor VIII was the major cost
driver [$48,772 ($802–$73,483)] comprising 94%
(37%–97%) of all expenditures. Average hospitalization
cost/patient was $1,190 ($0–$15,877), including surgery,
drugs, nursing care and stay. In total, there were 11 hos-
pitalizations [0.3 (0–1)/patient/year], which lasted 57 hos-
pital days [1.6 (0–8)/patient/year]. Treatment cost per
bleed was $613 ($0–$2875). Patients had 76 bleeds in
total [2.2 (0–14)/patient/year]. Catheter costs were $428
($0–$1975) and complications added $326 ($0–$727),
clinic visits contributed $572 ($484–$723) and home care
added $92 ($0–$371). Total costs increased linearly over
time [yearly cost = $4774.1 per year + $10,307 (r2 =
0.54)], as did Factor VIII cost [yearly cost = $5263 per
year + $3064 (r2 = 0.61)]. CONCLUSIONS: In this series
of severe hemophilia patients, prophylactic treatment was
found to be very expensive at more than $50,000 per
patient. However, the results were sensitive to the clotting
factor unit cost, which comprised 94% of the total
average cost/patient/year. For all patients, a decrease in
number of bleeds, hospitalizations and hospital days 
was observed over time, suggesting increasing quality of
life.
